Literature DB >> 2280770

Cross-linking of estrogen receptor to chromatin in intact MCF-7 human breast cancer cells: optimization and effect of ligand.

C K Wrenn1, B S Katzenellenbogen.   

Abstract

To investigate the effect of ligand (be it hormone, antihormone, or no hormone) on the interaction between estrogen receptor (ER) and chromatin, we have used formaldehyde as a cross-linking agent in intact MCF-7 human breast cancer cells. After a 1- to 2-h hormone treatment, the cells are exposed for 8 min to formaldehyde, which is added directly to their culture medium to minimize environmental perturbation. Nuclei are prepared from formaldehyde-treated cells and their contents are fractionated on CsCl density gradients to separate DNA-protein complexes from free protein. Peak gradient fractions are assayed for the presence of specific proteins by immunoblot of sodium dodecyl sulfate-polyacrylamide gel patterns. Using this approach, we find that 0.15% formaldehyde is optimal for cross-linking ER to chromatin. We detect ER and the large subunit of RNA polymerase II with DNA from formaldehyde-treated, but not from untreated cells. On the other hand, actin (a cytoplasmic protein) and small nuclear ribonucleoprotein particle proteins (nuclear RNA binding proteins) are not cross-linked to DNA. Therefore, cross-linking appears to be selective and fractionation is efficient. Interestingly, we detect similar levels of ER (as well as RNA polymerase II) with DNA from formaldehyde-treated cells, regardless of whether the cells are preexposed to estrogen (17 beta-estradiol at 10(-8) M), antiestrogen (ICI 164,384 at 10(-7) or 10(-6) M), or no hormone. These results, using covalent cross-linking in intact cells, indicate that both ligand-occupied and unoccupied ER are associated with chromatin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280770     DOI: 10.1210/mend-4-11-1647

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  8 in total

1.  Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity.

Authors:  P G Martini; R Delage-Mourroux; D M Kraichely; B S Katzenellenbogen
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Mitotic repression of RNA polymerase II transcription is accompanied by release of transcription elongation complexes.

Authors:  G G Parsons; C A Spencer
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  Estrogen-induced transcription of the progesterone receptor gene does not parallel estrogen receptor occupancy.

Authors:  Y J Lee; J Gorski
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens.

Authors:  J C Reese; B S Katzenellenbogen
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

5.  Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells.

Authors:  J C Reese; B S Katzenellenbogen
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

6.  Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor.

Authors:  W L Kraus; E M McInerney; B S Katzenellenbogen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

7.  Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors.

Authors:  T Ylikomi; M T Bocquel; M Berry; H Gronemeyer; P Chambon
Journal:  EMBO J       Date:  1992-10       Impact factor: 11.598

8.  Mitotic transcription repression in vivo in the absence of nucleosomal chromatin condensation.

Authors:  C A Spencer; M J Kruhlak; H L Jenkins; X Sun; D P Bazett-Jones
Journal:  J Cell Biol       Date:  2000-07-10       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.